ENGENE HOLDINGS INC (ENGN) Stock News

enGene to Participate in Upcoming Investor Conferences

Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now?

We recently published a list of 13 Best Canadian Penny Stocks to Invest in Now In this article, we are going to take a look at where enGene Holdings Inc. (NASDAQ:ENGN) stands against other best Canadian penny stocks to invest in now. We define penny stocks as shares trading under $5.00, which usually fall into […]

Mentions: DHI CMG

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Why enGene Holdings Stock Is Trading Higher

enGene shares are trading higher by 6.7% during Friday's session. The company announced it generated approximately $60 million in proceeds from a private placement.

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

enGene to Participate in the Leerink Partners Global Healthcare Conference

This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Mentions: VG SHLS ESLA ATYR

ENGN Stock Earnings: enGene Holdings Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips enGene Holdings (NASDAQ:ENGN) just reported results for the second quarter of 2...

ENGN Stock Earnings: enGene Holdings Misses EPS for Q2 2024

ENGN stock results show that enGene Holdings missed analyst estimates for earnings per share the second quarter of 2024.

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

enGene to Participate in Upcoming Investor Conferences

enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

enGene Announces $60 Million Private Placement Financing

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

enGene to Participate in Upcoming Investor Conferences

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

Mentions: NAMS APGE SYRE VECT

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

enGene to Present at the Jefferies Global Healthcare Conference

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors